Cryptocurrency Exchange and Custodian Gemini Selects Eventus Systems as Trade Surveillance Provider
Eventus continues growth in digital asset space as Validus platform leveraged by major crypto exchanges
Eventus Systems, Inc., a multi-award winning global trade surveillance and risk management software platform provider, announced that Gemini Trust Company, LLC (Gemini), a leading cryptocurrency exchange and custodian, has selected Eventus’ Validus platform for the exchange’s new trade surveillance solution. The signing marks the sixth major exchange in the digital asset space to turn to Eventus for trade surveillance.
Recommended AI News: MayaData Announces Record Growth in Community Adoption and Revenues
Gemini has adopted the cloud-based version of Validus on a T+1 basis for market surveillance that identifies a wide range of potential market manipulation behaviors.
Recommended AI News: SHL Redefines How Organizations Shape Their Talent Management Strategies
Gemini Chief Operating Officer Noah Perlman said: “The digital asset space is a constantly changing environment, and working with a solution that is tailored for our market needs, including built-in flexibility as the landscape evolves, is critical. Eventus has a great track record, and its solution combines strong machine-learning and automation capabilities alongside a high-touch support model.”
Eventus CEO Travis Schwab said: “We are thrilled to provide our trade surveillance platform for one of the most established cryptocurrency exchanges on the market. In the past two years, we have significantly enhanced our capabilities in the digital asset place as more exchanges and market participants turn to us for our expertise in the area. As digital assets grow in popularity, it’s more important than ever that marketplaces like Gemini establish comprehensive trade surveillance programs and procedures to ensure they remain constantly vigilant to address any potential threats of market abuse.”
Recommended AI News: Using AI and Machine Learning for Repurposing Drugs as Potential COVID-19 Therapies